AMENDMENT NUMBER ONE TO RESEARCH AND LICENSE AGREEMENTResearch and License Agreement • May 3rd, 2010 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations
THIS AMENDMENT (the “Amendment”) to the Research and License Agreement of February 5, 2009 is made and entered into as of the 27th day of April, 2010 by and between Trevena, Inc., a Delaware corporation, having a principal address at 1018 West 8th Ave. Building 11, King of Prussia, Pennsylvania 19406 (“Company”), and Ligand Pharmaceuticals Incorporated, a Delaware corporation, having its principal place of business at 11085 North Torrey Pines Road, Suite 300, La Jolla, CA 92037 (“Ligand”).
